Abstracts tagged "scleroderma and systemic sclerosis"

Abstract Number: 2907 • 2013 ACR/ARHP Annual Meeting
D1398G Variant Of Hepatocyte Growth Factor Receptor – A Potential Biomarker Of Severe Interstitial Lung Disease In African American Scleroderma Patients
Ilia Atanelishvili¹, Tanjina Akter², Richard M. Silver³ and Galina S. Bogatkevich², ¹Division of Rheumatology & Immunology, Medical University of South Carolina,Charleston,USA, Charleston, SC, ²Department of Rheumatology, Medical University of South Carolina,Charleston,USA, Charleston, SC, ³Div Rheumatology & Immunology, Medical University of South Carolina,Charleston,USA, Charleston, SC
Background/Purpose: Interstitial lung disease (ILD) is a major complication and leading cause of mortality in scleroderma (SSc, systemic sclerosis). The morbidity and mortality rates in…
Abstract Number: 2917 • 2013 ACR/ARHP Annual Meeting
Mortality, Recurrence, and Hospital Course of Patients With Systemic Sclerosis Related Acute Intestinal Pseudo-Obstruction
Chris T. Derk¹, Nora Sandorfi², Shivani Purohit³ and Christopher Mecoli⁴, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Division of Rheumatology, Thomas Jefferson Univ Med Coll, Philadelphia, PA, ³Rheumatology Division, Department of Medicine, Rheumatology Division, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, ⁴Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Acute intestinal pseudo-obstruction is a rare gastrointestinal manifestation of SSc with little data existing as to the demographics, clinical course, outcomes and mortality of…
Abstract Number: 2739 • 2013 ACR/ARHP Annual Meeting
Immunochip Analysis Identifies New Susceptibility Loci For Systemic Sclerosis: Implications For Pathogenesis
Maureen D. Mayes for the US Scleroderma GWAS Group¹, Lara Bossini-Castillo for the Spanish Scleroderma Group², Olga Gorlova³, Jose Ezequiel Martin⁴, Xiaodong Zhou¹, Wei Chen⁵, Shervin Assassi¹, Jun Ying⁵, John D. Reveille¹, Peter K. Gregersen⁶, Annette T. Lee⁷, Maria Teruel⁸, Francisco David Carmona⁴, Bobby P.C. Koeleman⁹, Matthew A. Brown and the Immunochip Consortium¹⁰, Christopher P. Denton¹¹, Murray Baron for the Canadian Scleroderma Research Group¹², Jasper Broen¹³, T.R.D.J. Radstake¹³ and Javier Martin⁴, ¹Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ²Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, ³Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, ⁴Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain, ⁵Department of Epidemiology, UT M.D. Anderson Cancer Center, Houston, TX, ⁶Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁷Genomics & Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁸Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, ⁹Department of Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands, ¹⁰Translational Research Institute, University of Queensland Diamantina Institute, Brisbane, Australia, ¹¹Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ¹²Rheumatology, Jewish General Hospital, Montreal, QC, Canada, ¹³Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose : The purpose of this study was to identify SSc risk loci shared with other autoimmune diseases on the Immunochip and to fine-map previously…
Abstract Number: 2609 • 2013 ACR/ARHP Annual Meeting
Dutch Translation and Validation Of The University of California, Los Angeles scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument 2.0
Jessica Meijs¹, Daisy Pors¹, Theodora P.M. Vliet Vlieland², Tom W.J. Huizinga¹ and Annemie J.M. Schuerwegh¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Orthopaedics, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Gastrointestinal tract (GIT) involvement occurs in approximately 90% of the patients with systemic sclerosis (SSc) and leads to a decrease in health-related quality of…
Abstract Number: 2582 • 2013 ACR/ARHP Annual Meeting
Treatment Of Pulmonary Hypertension In Scleroderma Patients With Restricitive Lung Disease.Observations From The Pulmonary Hypertension Assessment and Recognition Of Outcomes In Scleroderma Cohort
Virginia D. Steen¹ and Robyn T. Domsic², ¹Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ²Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Trials of therapy in pulmonary hypertension(PH) have generally excluded patients with significant interstitial lung disease, but many patients with systemic sclerosis(SSc) and PH have…
Abstract Number: 2576 • 2013 ACR/ARHP Annual Meeting
Epoprostenol Rescue Therapy In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension
Adrienne M. Roos¹, Christopher Pasarikovski¹, Amie T. Kron¹, John T. Granton², Peter Lee³, John Thenganatt⁴ and Sindhu R. Johnson⁵, ¹Medicine, Toronto Scleroderma Research Program, Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada, ²Medicine, Toronto Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Canada, ³Lebovic Bldg, Mt. Sinai Hospital, Toronto, ON, Canada, ⁴Medicine, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Divisions of Respirology and Critical Care Medicine, Toronto, ON, Canada, ⁵Medicine, Division of Rheumatology, Toronto Western Hospital, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Epoprostenol has been demonstrated to improve hemodynamics, functional class, and six-minute walk distance (6MWD) in systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) and idiopathic PAH…
Abstract Number: 2577 • 2013 ACR/ARHP Annual Meeting
Sex Disparities In Survival Of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension Patients
Christopher Pasarikovski¹, John T. Granton², Peter Lee³, Adrienne M. Roos¹, Amie T. Kron¹, Cathy Chau⁴ and Sindhu R. Johnson⁵, ¹Medicine, Toronto Scleroderma Research Program, Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada, ²Medicine, Toronto Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Canada, ³Lebovic Bldg, Mt. Sinai Hospital, Toronto, ON, Canada, ⁴Medicine, Toronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Medicine, Toronto Western Hospital, Toronto General Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic sclerosis (SSc) associated pulmonary arterial hypertension (PAH) and idiopathic PAH (IPAH) are conditions with poor survival. There is evidence to suggest that sex…
Abstract Number: 1810 • 2013 ACR/ARHP Annual Meeting
Evaluation Of The New American College Of Rheumatology/European League Against Rheumatism Criteria For The Classification Of Systemic Sclerosis In The Canadian Scleroderma Research Group Cohort
Hebah Alhajeri¹, Marie Hudson², Marvin J. Fritzler³, Janet E. Pope⁴, Canadian Scleroderma Research Group -⁵ and Murray Baron⁶, ¹Rheumatology, McGill University, Montreal, QC, Canada, ²Rheumatology, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ³Medicine, University of Calgary, Calgary, AB, Canada, ⁴St Joseph Health Care, London, ON, Canada, ⁵Jewish General Hospital, Montreal, QC, Canada, ⁶Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: New classification criteria for systemic sclerosis (SSc) have recently been developed. In this study, we aimed to assess the sensitivity of this classification in…
Abstract Number: 1811 • 2013 ACR/ARHP Annual Meeting
Validation Of The ICD-CM-9 Code For Systemic Sclerosis Using Updated ACR/EULAR Classification Criteria
Aaliya Yaqub¹, Lorinda Chung², David Fiorentino³ and Eswar Krishnan⁴, ¹Stanford Univ Medical Center, Stanford, CA, ²Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ³Dermatology, Stanford University School of Medicine, Redwood City, CA, ⁴Medicine, Stanford University, Palo Alto, CA
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease associated with substantial morbidity. Epidemiologic studies using large administrative databases often rely on the accuracy of…
Abstract Number: 853 • 2012 ACR/ARHP Annual Meeting
Systemic Sclerosis Classification Criteria: Developing Methods for Multi-Criteria Decision Analysis
Sindhu R. Johnson¹, Raymond P. Naden², Jaap Fransen³, Frank H.J. van den Hoogen⁴, Janet E. Pope⁵, Murray Baron⁶, Alan G. Tyndall⁷, Marco Matucci-Cerinic⁸ and Dinesh Khanna on behalf of ACR/EULAR Classification Criteria SSc⁹, ¹Dept of Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ²Auckland City Hospital, Auckland, New Zealand, Austria, ³Rheumatic Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Rheumatology, Rheumatology Centre Sint Maartenskliniek and Radboud university medical center, Ubbergen (Nijmegen), Netherlands, ⁵Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ⁶Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ⁷Rheumatology, University of Basel, Basel, Switzerland, ⁸Medicine, Univ Florence, Firenze, Italy, ⁹Div of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Classification criteria for systemic sclerosis (SSc) are being developed. Twenty-three candidate criteria have been identified, but need to be reduced. The objectives of this…
Abstract Number: 711 • 2012 ACR/ARHP Annual Meeting
Myopathy Is a Poor Prognostic Feature in Systemic Sclerosis: Results From the Canadian Scleroderma Research Group
MIchelle Jung¹, Murray Baron², Marie Hudson³, Ashley Bonner⁴, Janet E. Pope⁵ and Canadian Scleroderma Research Group⁶, ¹Western University, London, ON, Canada, ²Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ³Jewish General Hospital, McGill University, Montreal, QC, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ⁶Montreal, QC, Canada
Background/Purpose: Myopathy / myositis is associated with more severe systemic scleroderma (SSc). The aim of this study was to determine such clinical information from the…
Abstract Number: 720 • 2012 ACR/ARHP Annual Meeting
Left-Heart Disease Is a Frequent Cause of Pulmonary Hypertension in Systemic Sclerosis, Is Associated with Increased Levels of MR-ProANP and MR-ProADM but Is Unrelated to Elevated NT-ProBNP Levels: A Retrospective Cohort Analysis
Lada Miller¹, Sandra Chartrand¹, Martial Koenig², Jean-Richard Goulet³, Eric Rich¹, Michal Abrahamowicz⁴, Jean-Luc Senécal¹ and Tamara Grodzicky¹, ¹Rheumatology, Hôpital Notre-Dame du CHUM, Montreal, QC, Canada, ²Internal Medicine, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada, ³Rheumatology, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada, ⁴Centre Universitaire de Santé McGill (CUSM), Montreal, QC, Canada
Background/Purpose: Pulmonary hypertension (PH) is a significant cause of morbidity and mortality in systemic sclerosis (SSc). Pulmonary arterial hypertension (PAH) is reportedly the most frequent…
Abstract Number: 721 • 2012 ACR/ARHP Annual Meeting
Measurement of Pulmonary Arteries by Cardiac Magnetic Resonance Imaging: A Simple and Useful Tool for the Detection of Pulmonary Hypertension in Systemic Sclerosis Patients without Overt Cardiac Microvascular Perfusion Defects or Fibrosis
Sandra Chartrand¹, Lada Miller¹, Martial Koenig², Jean-Richard Goulet¹, Eric Rich¹, Anne S. Chin³, Yves Provost³, Carl Chartrand-Lefebvre³, Pauline Gou¹, Jean-Luc Senécal¹ and Tamara Grodzicky¹, ¹Rheumatology, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada, ²Internal Medicine, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada, ³Radiology, Hôtel-Dieu de Montréal du CHUM, Montréal, QC, Canada
Background/Purpose: Pulmonary hypertension (PH) is a major complication of systemic sclerosis (SSc). We observed that a significant proportion of our SSc patients with PH as…
Abstract Number: 710 • 2012 ACR/ARHP Annual Meeting
Optical Density Measure of the Papillary Dermis Discriminates As Abnormal Clinically Uninvolved Skin in Systemic Sclerosis and Correlates with Severity of Skin Thickness
Giuseppina Abignano¹, Sibel Z. Aydin², Concepcion Castillo-Gallego³, Daniel Woods⁴, Adam Meekings⁵, Dennis McGonagle⁶, Paul Emery⁷ and Francesco Del Galdo⁸, ¹Chapel Allerton Hospital Leeds Insitute of Molecular medicine, Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, ²Unit of Rheumatology, Medeniyet University, Goztepe Training and Research Hospital, Istanbul, Turkey, ³Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ⁴Michelson Diagnostics Ltd, Kent, United Kingdom, ⁵Michelson Diagnostics Ltd, Kent, United Kingdom, Kent, United Kingdom, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁷Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, ⁸Musculoskeletal Diseases, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom
Background/Purpose: Skin involvement in systemic sclerosis (SSc) is often primary outcome in clinical trials and its severity inversely correlates with prognosis. Nevertheless, an objective quantitative…
Abstract Number: 92 • 2012 ACR/ARHP Annual Meeting
Combined Response Index in Diffuse Systemic Sclerosis (CRISS)—Which External Anchors to Use When Developing the Index? Baseline Analysis
Dinesh Khanna¹, Veronica Berrocal², James R. Seibold³, Peter A. Merkel⁴, Maureen D. Mayes⁵, Kristine Phillips⁶, Robert W. Simms⁷, Shervin Assassi⁵, Philip J. Clements⁸ and Daniel Furst⁹, ¹Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²Div of Rheumatology, University of Michigan, Ann Arbor, MI, ³Scleroderma Research Consultants LLC, Avon, CT, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁶Rheumatology, University of Michigan, Ann Arbor, MI, ⁷Rheumatology, Boston University School of Medicine, Boston, MA, ⁸University of California, Los Angeles, Department of Medicine, Los Angeles, CA, ⁹Div of Rheumatology, UCLA Medical School, Los Angeles, CA
Background/Purpose: As part of an NIH sponsored effort to develop a data-driven CRISS, we evaluated the face, content, and construct validity (convergent and discriminant) of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.